Please login to the form below
Sage
This page shows the latest Sage news and features for those working in and with pharma, biotech and healthcare.
Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3
Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies. ... In November 2020, Biogen signed a $3.1bn deal focused on a series of potential depression and movement disorder therapies under development by Sage.
Latest news
-
First shipments of AZ/Oxford COVID-19 vaccine sent through COVAX
The WHO’s Strategic Advisory Group of Experts (Sage) backed use of the jab in adults, including those aged over 65, despite some EU countries having ruled out giving the vaccine ... The Sage panel also recommended that the vaccine should be
-
WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine
The formal EUL follows a recommendation from the WHO’s Strategic Advisory Group of Experts (Sage) last week that backed the use of the vaccine in adults, including those aged over ... This dosing interval was recommend by the WHO’s Sage, which also
-
WHO backs AZ/Oxford COVID-19 vaccine, including in older adults
WHO's Sage panel also recommends a two-dose regimen given eight to 12 weeks apart. ... The Sage panel has also recommended that the vaccine should be administered as two doses, given eight to 12 weeks apart.
-
WHO advises both doses of Pfizer/BioNTech’s COVID-19 vaccine within a 21-28 day schedule
The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) added, however, that countries should be able to administer the two doses over six weeks to ensure more high-priority ... SAGE made a provision for countries in exceptional
-
Biogen signs $3.1bn deal with Sage for potential depression therapies
Biogen has bet up to $3.1bn on a series of potential depression and movement disorder therapies currently being developed by Sage Therapeutics. ... In the US, Biogen and Sage will share responsibility and costs for development, as well as profits and
First shipments of AZ/Oxford COVID-19 vaccine sent through COVAX
WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine
WHO advises both doses of Pfizer/BioNTech’s COVID-19 vaccine within a 21-28 day schedule
Biogen signs $3.1bn deal with Sage for potential depression therapies
More from news
Approximately 9 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
How will COVID-19 affect uptake of vaccinations against other diseases?
Interim guidance published by the WHO Strategic Advisory Group of Experts (SAGE) on 21 September suggests that there is a need to reconsider the prioritisation of risk groups for influenza vaccination
-
How merging firms can manage culture change
Globally, we've seen a deal struck between US firms Abbott and Alere for $5.8bn, while on the same day Stryker agreed to buy Sage for around $2.8bn.
-
Deal Watch February 2016
Turning to medtech, Stryker has had a busy month acquiring two companies, Sage Products and Physio-Control, paying over $4bn in cash for the two transactions. ... acquisition - company. 5, 800. Sage Products/ Stryker Corporation. portfolio of disposable
How will COVID-19 affect uptake of vaccinations against other diseases?
How merging firms can manage culture change
Deal Watch February 2016
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Horizon Discovery appoints executive director
Smoller joined Horizon as chief business officer as part of the form's acquisition of Sage Labs for $48m in September this year. ... company.”. His previous roles include the position of CEO at Sage Labs, chief scientific officer of Sigma-Aldrich and
-
Evoke Pharma adds to executive team
Dr Alves joins from Sage Clinical Development where he served as president and principal consultant.
-
Blue Latitude boosts senior management team
During her time as director of del Galdo Consulting, del Galdo worked with GSK &Ogilvy Common Health, Freesat, Thomson Reuters, Human Factors International, HomeAway, Sage, and Further on a variety of
-
Shires's Jeffrey Jonas to lead Sage
CNS appoints CEO alongside new CMO and CFO. Sage Therapeutics has made several changes at the top level, including the appointment of Shire's Dr Jeffrey Jonas as CEO. ... The changes come two years after the formation of the central nervous system (CNS)
Horizon Discovery appoints executive director
Evoke Pharma adds to executive team
Blue Latitude boosts senior management team
Shires's Jeffrey Jonas to lead Sage
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Sandoz completes acquisition of GSK’s cephalosporin business
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- US demand for COVID-19 antibody treatments rising fast
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- David Hunt launches independent agency The Considered
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
